Director/PDMR Shareholding
("Renalytix" or the "Company")
Director/PDMR Dealing
The Company had been informed today that
Following completion of the sale,
For further information, please contact:
Renalytix plc |
||
|
Via Walbrook PR |
|
|
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
|
|
Investec Bank plc (Joint Broker) |
Tel: 020 7597 4000 |
|
|
|
|
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
|
Mob: 07980 541 893 / 07584 391 303 |
|
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
1 https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About KidneyIntelX
KidneyIntelX, is a first-of-kind, bioprognosticTM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
Name
|
Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited |
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Christopher Mills, the issuer's interim chairman, is Chief Executive Officer of Harwood |
|||
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
Renalytix AI plc |
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of £0.0025 each |
|||
|
|
||||
Identification code |
GB00BYWL4Y04
|
||||
|
|
||||
b)
|
Nature of the transaction
|
Sale of shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
£11.25 |
6,100 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
6,100 |
||||
|
|
||||
- Price |
£68,625.00 |
||||
|
|
||||
e)
|
Date of the transaction
|
25 June 2021 |
|||
f)
|
Place of the transaction
|
London Stock Exchange |
information is provided by RNS, the news service of the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the